Skip to main content

Advertisement

SpringerLink
Log in

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords “metastasectomy,” “renal cell carcinoma,” and “targeted therapy,” and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1):78–83. doi:10.1002/cncr.23518

    Article  PubMed  Google Scholar 

  2. Chen DY, Uzzo RG (2009) Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw: JNCCN 7(6):635–642 quiz 643

    PubMed Central  PubMed  Google Scholar 

  3. Russo P (2011) The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 25(4):737–752. doi:10.1016/j.hoc.2011.04.009

    Article  PubMed  Google Scholar 

  4. Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 10(18 Pt 2):6335S–6341S. doi:10.1158/1078-0432.CCR-sup-040026

    Article  Google Scholar 

  5. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970

    Article  CAS  PubMed  Google Scholar 

  6. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5):824–832

    Article  CAS  PubMed  Google Scholar 

  7. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316(15):889–897. doi:10.1056/nejm198704093161501

    Article  CAS  PubMed  Google Scholar 

  8. Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol: Off J Am Soc Clin Oncol 11(9):1809–1816

    CAS  Google Scholar 

  9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer: the Cochrane database of systematic reviews (1):CD001425. doi:10.1002/14651858.CD001425.pub2

  10. Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127(11):1343–1349 Chicago Ill: 1960

    Article  CAS  PubMed  Google Scholar 

  11. Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937

    Article  CAS  PubMed  Google Scholar 

  12. Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5):375–381. doi:10.1097/MOU.0b013e32833c7ada

    Article  PubMed  Google Scholar 

  13. Russo P, O’Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35(4):679–686. doi:10.1016/j.ucl.2008.07.009

    Article  PubMed  Google Scholar 

  14. Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8(4):180–181. doi:10.1038/nrurol.2011.30

    Article  PubMed  Google Scholar 

  15. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(1):16–24. doi:10.1200/jco.2005.02.2574

    Article  CAS  Google Scholar 

  16. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(16):2505–2512. doi:10.1200/jco.2005.03.6723

    Article  CAS  Google Scholar 

  17. Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96(3):286–290. doi:10.1111/j.1464-410X.2005.05616.x

    Article  CAS  PubMed  Google Scholar 

  18. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a cochrane systematic review of published randomised trials. BJU Int 108(10):1556–1563. doi:10.1111/j.1464-410X.2011.10629.x

    Article  CAS  PubMed  Google Scholar 

  19. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158(5):1691–1695

    Article  CAS  PubMed  Google Scholar 

  20. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 17(8):2530–2540

    CAS  Google Scholar 

  21. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 23(4):832–841. doi:10.1200/JCO.2005.05.179

    Article  Google Scholar 

  22. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 20(1):289–296

    Article  CAS  Google Scholar 

  23. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3):873–878. doi:10.1016/j.juro.2008.05.006 discussion 878

    Article  PubMed Central  PubMed  Google Scholar 

  24. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98(12):2566–2575. doi:10.1002/cncr.11851

    Article  PubMed  Google Scholar 

  25. Lara PN, Jr., Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S (2009) Predictors of survival of advanced renal cell carcinoma: long-term results from southwest oncology group trial S8949. J Urol 181(2):512–516. doi:10.1016/j.juro.2008.10.021 discussion 516–517

    Article  Google Scholar 

  26. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 16(6):2261–2266

    CAS  Google Scholar 

  27. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48(1):77–81. doi:10.1016/j.eururo.2005.03.004 discussion 81–72

    Article  PubMed  Google Scholar 

  28. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi:10.1002/cncr.25836

    Article  PubMed  Google Scholar 

  29. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Off J Am Soc Clin Oncol 27(34):5794–5799. doi:10.1200/JCO.2008.21.4809

    Article  CAS  Google Scholar 

  30. Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82(4):846–851. doi:10.1016/j.urology.2013.06.035

    Article  PubMed  Google Scholar 

  31. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I (2006) Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5(3):232–234. doi:10.3816/CGC.2006.n.042

    Article  PubMed  Google Scholar 

  32. Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC (2009) Surgical resection of renal cell carcinoma after targeted therapy. J Urol 182(3):881–886. doi:10.1016/j.juro.2009.05.014

    Article  PubMed  Google Scholar 

  33. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444. doi:10.1016/j.juro.2010.09.086

    Article  PubMed  Google Scholar 

  34. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. doi:10.1093/annonc/mdr362

    Article  CAS  PubMed  Google Scholar 

  35. Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, Grundmann E, Eder M, Zwicknagl M et al (1988) Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 114(6):605–612

    Article  CAS  PubMed  Google Scholar 

  36. Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung. J Urol 42:269–276

    Google Scholar 

  37. Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54(1):33–38

    Article  CAS  PubMed  Google Scholar 

  38. Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79(3):996–1003. doi:10.1016/j.athoracsur.2004.08.034

    Article  PubMed  Google Scholar 

  39. Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57(2):339–344

    Article  CAS  PubMed  Google Scholar 

  40. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74(5):1653–1657

    Article  PubMed  Google Scholar 

  41. Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M (2007) Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 84(4):1114–1120. doi:10.1016/j.athoracsur.2007.04.118

    Article  PubMed  Google Scholar 

  42. Assouad J, Riquet M, Berna P, Danel C (2007) Intrapulmonary lymph node metastasis and renal cell carcinoma. Eur J Cardiothorac Surg 31(1):132–134. doi:10.1016/j.ejcts.2006.10.025

    Article  PubMed  Google Scholar 

  43. Reinke RT, Higgins CB, Niwayama G, Harris RH, Friedman PJ (1976) Bilateral pulmonary hilar lymphadenopathy: an unusual manifestation of metastatic renal cell carcinoma. Radiology 121(1):49–53. doi:10.1148/121.1.49

    Article  CAS  PubMed  Google Scholar 

  44. Winter H, Meimarakis G, Angele MK, Hummel M, Staehler M, Hoffmann RT, Hatz RA, Lohe F (2010) Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J Urol 184(5):1888–1894. doi:10.1016/j.juro.2010.06.096

    Article  PubMed  Google Scholar 

  45. Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, Nagahara A, Nakai Y, Takayama H, Inoue M, Shiono H, Nishimura K, Okumura M, Nonomura N (2011) Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol 16(6):660–665. doi:10.1007/s10147-011-0244-0

    Article  PubMed  Google Scholar 

  46. Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 202(2):158–167. doi:10.1016/j.amjsurg.2010.06.029

    Article  PubMed  Google Scholar 

  47. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2013) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. doi:10.1016/j.eururo.2013.08.012

    PubMed  Google Scholar 

  48. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(4):1185–1192. doi:10.1016/j.ijrobp.2009.03.062

    Article  PubMed  Google Scholar 

  49. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. doi:10.1093/annonc/mdq554

    Article  CAS  PubMed  Google Scholar 

  50. Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: the princess Margaret experience. Am J Clin Oncol 31(2):182–187. doi:10.1097/COC.0b013e3181574084

    Article  CAS  PubMed  Google Scholar 

  51. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219

    Article  CAS  PubMed  Google Scholar 

  52. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2):295–300. doi:10.1093/annonc/mdq342

    Article  CAS  PubMed  Google Scholar 

  53. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794–1801. doi:10.2106/JBJS.F.00603

    Article  PubMed  Google Scholar 

  54. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R, Group EGTC (2009) Radical nephrectomy with and without lymph-node dissection: final results of European organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1):28–34. doi:10.1016/j.eururo.2008.09.052

    Article  Google Scholar 

  55. Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H (2011) Lymph node dissection in renal cell carcinoma. Eur Urol 60(6):1212–1220. doi:10.1016/j.eururo.2011.09.003

    Article  PubMed  Google Scholar 

  56. Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML (2008) Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 180(1):99–103. doi:10.1016/j.juro.2008.03.025

    Article  PubMed  Google Scholar 

  57. Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul brousse hospital experience. HPB 8(2):100–105. doi:10.1080/13651820500496266

    Article  PubMed Central  PubMed  Google Scholar 

  58. Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM (2012) A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 14(8):532–538. doi:10.1111/j.1477-2574.2012.00495.x

    Article  PubMed Central  PubMed  Google Scholar 

  59. Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM (2011) Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 18(7):1932–1938. doi:10.1245/s10434-010-1526-x

    Article  PubMed Central  PubMed  Google Scholar 

  60. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98(2):342–349. doi:10.3171/jns.2003.98.2.0342

    Article  PubMed  Google Scholar 

  61. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113(7):1641–1648. doi:10.1002/cncr.23769

    Article  PubMed  Google Scholar 

  62. Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53(2):376–381. doi:10.1016/j.eururo.2007.08.053

    Article  CAS  PubMed  Google Scholar 

  63. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27(6C):4255–4257

    CAS  PubMed  Google Scholar 

  64. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958–4965. doi:10.1002/cncr.26138

    Article  CAS  PubMed  Google Scholar 

  65. Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679–686. doi:10.1097/CCO.0b013e3283571a1c

    Article  CAS  PubMed  Google Scholar 

  66. Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL (2012) The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116(5):978–983. doi:10.3171/2012.2.JNS111353

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96(6):579–592. doi:10.1002/bjs.6606

    Article  CAS  PubMed  Google Scholar 

  68. Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M (2012) Metastases to the thyroid: a review of the literature from the last decade. Thyroid 22(3):258–268. doi:10.1089/thy.2010.0154

    Article  PubMed  Google Scholar 

  69. Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H (2013) Metastasis to the thyroid gland: report of a large series from the mayo clinic. Am J Clin Oncol. doi:10.1097/COC.0b013e31829d1d09

    PubMed  Google Scholar 

  70. Antonelli A, Arrighi N, Corti S, Legramanti S, Zanotelli T, Cozzoli A, Cunico SC, Simeone C (2012) Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int 110(11 Pt B):E559–E563. doi:10.1111/j.1464-410X.2012.11271.x

    Article  PubMed  Google Scholar 

  71. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW (2011) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):Vi25–vi30. doi:10.1093/annonc/mdr372

    PubMed  Google Scholar 

  72. Ismaili N (2011) Treatment of colorectal liver metastases. World J Surg Oncol 9:154. doi:10.1186/1477-7819-9-154

    Article  PubMed Central  PubMed  Google Scholar 

  73. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E (2009) Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456–460. doi:10.1111/j.1464-410X.2009.08490.x

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Dae Y. Kim: None; Jose A. Karam: Pfizer Consultant; Christopher G. Wood: Pfizer Research Investigator, Argos Research Investigator, and GlaxoSmithKline Research Investigator.

Author information

Authors and Affiliations

  1. MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX, 77030, USA

    Dae Y. Kim, Jose A. Karam & Christopher G. Wood

Authors
  1. Dae Y. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose A. Karam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher G. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher G. Wood.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, D.Y., Karam, J.A. & Wood, C.G. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol 32, 631–642 (2014). https://doi.org/10.1007/s00345-014-1293-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1293-6

Keywords

Search

Navigation